Manipal Hospitals to Acquire Sahyadri for ₹6,400 Cr in Major Healthcare Deal

New Delhi — In a major development in India’s private healthcare landscape, Manipal Hospitals has sought approval from the Competition Commission of India (CCI) to acquire Sahyadri Hospitals, a leading Western India-based hospital chain, for a reported ₹6,400 crore.

This strategic move is expected to bolster Manipal’s footprint in Maharashtra and consolidate its position as one of the top three hospital networks in the country by bed capacity and revenue.

🏥 Sahyadri’s Presence:

Sahyadri Hospitals operates nine multi-speciality hospitals across cities like Pune, Nashik, and Karad, with a total bed strength of over 900 beds. The chain is known for its strong clinical specialties in oncology, neurology, cardiology, and organ transplants.

💼 Strategic Push by Manipal:

Manipal Hospitals, backed by global investment firm TPG Capital, has been actively expanding. The group previously acquired Columbia Asia and Vikram Hospital, building one of India’s largest integrated health networks.

This latest deal signals continued consolidation in India’s private healthcare market, driven by the rising demand for quality tertiary care, operational synergies, and access to underserved regional hubs.

🔍 What Comes Next:

The acquisition plan now awaits CCI’s approval, which is a mandatory regulatory step to ensure compliance with India’s antitrust laws. If cleared, the integration is likely to enhance patient access to Manipal’s standardised protocols, advanced medical tech, and streamlined care delivery across Western India.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices